Histone Deacetylase Inhibitor VI
     
Home > PRODUCTS > Biochemicals > Histone Deacetylase Inhibitor VI

Academic Discounts 2018

Newsletter Subscription

Stay updated with our new products and services. You can unsubscribe at any time.


Histone Deacetylase Inhibitor VI

N-Hydroxy-7-(2-naphthalenylthio)-heptanamide (HNHA)
HNHA is a cell-permeable inhibitor of histone deacetylase (HDAC) activity (IC50 = 100 nM)

Histone_Deacetylase_Inhibitor_VI

OTAVAchemicals Catalogue Number: 7070707016
CAS Registry Number: 926908-04-5
Purity: 95%+ (HPLC)


Ref.: Kim et al. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio)heptanomide, a novel histone deacetylase inhibitor. Biochemical and Biophysical Research Communications (2007), 356, 233-238


Abstract: N-Hydroxy-7-(2-naphthylthio)heptanamide (HNHA) is a histone deacetylase (HDAC) inhibitor with antitumor activity both in vitro and in vivo. The compound inhibited HDAC enzyme activity as well as proliferation of human fibrosarcoma cells (HT1080) in vitro. Treatment of cells with HNHA elicited histone hyperacetylation leading to an up-regulation of p21 transcription, cell cycle arrest, and an inhibition of HT1080 cell invasion. Moreover, HNHA effectively inhibited the growth of tumor tissue in a mouse xenograph assay in vivo. Together, these data demonstrate that this novel HDAC inhibitor could be developed as a potential antitumor agent targeting HDAC.

 
SSL